Date
Effective April 3, 2025, Cinvanti® will once again be a non-preferred agent in the Antiemetic 5-HT3 and NK1 Agents, Injectable PDL Edit. Cinvanti was temporarily changed to a preferred agent last fall during the shortage on IV fluids following the effects of Hurricane Helene in North Carolina. Baxter stated in their February 17, 2025 update that manufacturing has now returned to pre-hurricane levels. Fosaprepitant vials remain a preferred agent in the Antiemetic 5-HT3 and NK1 Agents, Injectable PDL Edit (Antiemetic 5-HT3, NK1 Agents, Injectable PDL Edit | mydss.mo.gov).